Introduction: Treatment Landscape of MDS
Published Online: Thursday, January 9, 2014
For High-Definition, ClickModerator, Harry P. Erba, MD, PhD, introduces a panel discussion exploring recent advances and future strategies for myelodysplastic syndromes (MDS) and chronic myeloid leukemia (CML). The discussion includes expert perspectives from Mark J. Levis, MD, PhD, Elias J. Jabbour, MD, Rami S. Komrokji, MD, Ruben A. Mesa, MD, and Rafael Bejar, MD, PhD.
As a rare disease, diagnosis is a major concern in MDS. In general, the disorder is characterized by ineffective hematopoiesis, peripheral blood cytopenias, and increased risk of progression to acute leukemia. Additionally, Bejar notes, recent advances into the molecular pathogenesis of MDS have allowed for a genetic approach to diagnosis, although this is not yet routinely performed.
There is an approximate 16% discrepancy in the diagnoses made between the community setting and academic institution, where genetic tests are performed more regularly. To create an appropriate treatment plan the biology, pathology, and molecular markers should all be considered, Jabbour believes.
Until recently genetics were not officially incorporated into the diagnostic criteria for MDS, Komrokji states. Cytogenetic changes, such as deletion 5q, are now accepted for a provisional diagnosis, and criteria are beginning to focus more on incorporating molecular changes. Overall, Levis believes, molecular medicine is likely going to change the way MDS is diagnosed with a complete sea change in 5 to 10 years.
While genetics have predictive value, their prognostic value in MDS remains a challenge that still requires refinement, Komrokji believes. One of the ways to obtain more predictive value from genetics in MDS is through the development of more sophisticated targeted therapeutic options, such as those targeting the BCR-ABL mutation in CML, Bejar believes.
View More From This Discussion
Mark J. Levis, MD, PhDDirector, Adult Leukemia Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Elias J. Jabbour, MDAssociate Professor,
Department of Leukemia,
Division of Cancer Medicine,
MD Anderson Cancer Center, Houston, Texas
Rami S. Komrokji, MDClinical Director, Associate Member, Department of Malignant Hematology
H Lee Moffitt Cancer Center
Ruben A. Mesa, MDChair, Division of Hematology
& Medical Oncology, Mayo Clinic, Scottsdale, Arizona
Rafael Bejar, MD, PhDAssistant Professor of Medicine, Division of Hematology-Oncology
University of California, San Diego, La Jolla, California
Most Popular Right Now
Online CME Activities
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.